Evidence map›Paper›PMID 41543033›Full record

ArticleThe Laryngoscope2026

Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP.

Simon R Best, Aaron D Friedman, Clark A Rosen, Robert T Sataloff, Laura A Matrka, H Steven Sims, David E Rosow, Nabil F Saba, David G Lott, Adam M Klein and 8 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Simon R BestDivision of Laryngology, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0001-8699-033X
Aaron D FriedmanDivision of Laryngology, Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati Medical Center, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0001-5615-3442
Clark A RosenDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, California, USA.ORCID https://orcid.org/0000-0003-1571-1086
Robert T SataloffDepartment of Otolaryngology-Head and Neck Surgery, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0001-5146-6319
Laura A MatrkaDepartment of Otolaryngology-Head & Neck Surgery, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-9558-5202
H Steven SimsRush Otolaryngology-Head and Neck Surgery, Chicago, Illinois, USA.
David E RosowDepartment of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, USA.ORCID https://orcid.org/0000-0002-4289-0158
Nabil F SabaDepartment of Hematology and Medical Oncology, The Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
David G LottDivision of Laryngology, Mayo Clinic Arizona, Phoenix, Arizona, USA.ORCID https://orcid.org/0000-0001-6541-9687
Adam M KleinEmory Voice Center, Emory University School of Medicine, Atlanta, Georgia, USA.
Ted MauDivision of Laryngology, Stanford University School of Medicine, Palo Alto, California, USA.ORCID https://orcid.org/0000-0002-1804-6707
Milan R AminDepartment of Otolaryngology-Head and Neck Surgery, New York University Grossman School of Medicine, New York, New York, USA.
Kathryn A Wikenheiser-BrokampDivision of Pathology & Laboratory Medicine and Perinatal Institute Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Scott M NorbergCenter for Immuno-Oncology, Cancer for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Kim McClellanRecurrent Respiratory Papillomatosis Foundation, Lawrenceville, New Jersey, USA.
Geoffrey D YoungRecurrent Respiratory Papillomatosis Foundation, Lawrenceville, New Jersey, USA.
Clint T AllenSurgical Oncology Program, Cancer for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-6586-5804
Recurrent Respiratory Papillomatosis Foundation

Funding

Recurrent Respiratory Papillomatosis Foundation
6 · The paper itself

Abstract

objectiveWith regulatory approval of HPV-specific immunotherapy for recurrent respiratory papillomatosis (RRP) and growing experience with systemic bevacizumab, a management algorithm incorporating these medical treatments is warranted. DATA SOURCES AND

methodsRRP Foundation (RRPF) Key Opinion Leaders offer a proposed management algorithm for adults with RRP considering published literature and commercial drug availability.

resultsPreventative HPV vaccination should be considered for all patients. Determination of HPV type and pulmonary imaging are important for contemporary RRP patient care and assist in decision making. Risks and benefits of papilloma debulking as needed versus medical management of RRP must be deliberated on a patient case-by-case basis. HPV-specific immunotherapy that induces an HPV-specific T cell response to target the underlying HPV infection that is the cause of RRP is safe, offers the possibility of durable disease control following a short treatment course and is the recommended first-line medical treatment for patients who wish to avoid the risks of repeat procedural management. Papilloma disease control with systemic bevacizumab, which carries defined risks and must be continued for clinical benefit is the recommended second-line medical treatment for patients who do not achieve a complete response with immunotherapy and wish to continue medical management. For patients who elect to be treated with debulking procedures as needed, use of locally-administered adjuvant should be considered.

conclusionThis proposed management algorithm from the RRPF serves as a contemporary resource and information guide for adult patients with RRP and their physicians considering treatment options. LEVEL OF EVIDENCE: 5:

Indexed as

Papillomavirus InfectionsRespiratory Tract InfectionsAdultAlgorithmsBevacizumabHumansImmunotherapyPapillomavirus VaccinesBevacizumabPapillomavirus Vaccinesbevacizumabimmunotherapymanagement algorithmrecurrent respiratory papillomatosis

Identifiers

PMID41543033
PMCPMC13460614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.